Retinitis pigmentosa is a gradual deterioration of the ability of eyes to see. The defect in the eye is inflicted upon the light-sensitive tissue – the retina, which is the leading cause of blindness.
The disease affects 1 in 3,000 to 1 in 4,000 people in the world, which sums its total prevalence to be approximately 1.77 to 2.35 million people globally. However, still, there is no standard or approved therapy to cure the disease.
DelveInsight is adding another Newsletter to its series that focuses on the sight-threatening disease.
The newsletter provides a brief introduction of the indication - Retinitis pigmentosa, its epidemiological analysis, preponderance in different populations, treatment approaches, unmet needs in the Market, and upcoming therapies in the future.
The newsletter presents the analysis of the present Retinitis pigmentosa market scenario, key pharma companies working to drive the RP market in the coming decade, key collaborations, and partnerships that are driving the Market. Furthermore, the newsletter also lists a gist of the top conferences on the horizon along with the organizations supporting RP patients.
Fill up the form to get access to the newsletter.
Subscribe to our series for more such deep and rich insights into the pharma market.
Know more about What's covered:
- Indication overview
- Epidemiological trends
- Treatment approaches
- Key Companies
- Pipeline drugs
- Collaborations and deals in the domain
- R&D in the field
- Top conferences
- Support from International organizations